Login
$HALO
$96.50 -$3.77 (3.76%) Live

$HALO 8-K/A SEC Filings

Filed On Filing
09 Aug 2022 8-K/A: Financial Statements and Exhibits

On April 12, 2022, Halozyme Therapeutics, Inc. (the “Buyer”, “Halozyme”, “Parent”, “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Antares Pharma, Inc., a Delaware corporation (the “Seller” or “Antar...

02 Nov 2021 8-K/A: Results of Operations and Financial Condition

– Record Quarterly Royalties in the Third Quarter of $58.6 million Representing 145% Growth over Third Quarter 2020 –

12 Nov 2019 8-K/A: Costs Associated with Exit or Disposal Activities; Material Impairments

As previously disclosed on the Initial 8-K, on October 30, 2019, the Board of Directors of the Company approved a corporate restructuring to halt development activities for PEGPH20 and close the Company’s oncology operations. This decisi...

07 Jan 2015 8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure

On January 7, 2015, Halozyme, Therapeutics, Inc. (“Halozyme”) issued a press release containing information concerning its cash, cash equivalents and marketable securities (unaudited) at December 31, 2014. A copy of that press release is...

20 Feb 2007 8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

HAS BEEN REQUESTED IS OMITTED AND NOTED WITH “***.” AN UNREDACTED VERSION OF THIS

15 Dec 2006 8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

THIS LICENSE AND COLLABORATION AGREEMENT (“Agreement”) dated as of December 5, 2006 (“Effective Date”), is entered into between HALOZYME, INC., a California corporation (“Halozyme”), having a place of business at 11588 Sorrento Valley Ro...

20 May 2004 8-K/A: Changes in Control of Registrant

The Board of Directors and Shareholders DeliaTroph Pharmaceuticals, Inc.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support